论文部分内容阅读
加替沙星(Gatifloxacin)是新型氟喹诺酮类药物,由日本杏林制药株式会社研制开发,BMS公司于’1999年12月在美国首先上市。2003年3月由我院药事管理委员会通过新药引进,进入我院临床使用。2003年8月进入湖北省招标目录,广泛在湖北省武汉地区使用。由于加替沙星具有抗菌作用强、临床疗效和安全性好的优点,加上用药方便,每日只需给药一次,病人依从性好,故生产厂家多,在医院内竞争激烈,现将本院加替沙星应用情况进行分析。1资料与方法
Gatifloxacin is a new type of fluoroquinolones, developed by Japan’s Kyorin Pharmaceutical Co., Ltd., BMS company in December 1999 in the United States first listed. March 2003 by our hospital Pharmacy Management Committee through the introduction of new drugs into our hospital for clinical use. August 2003 entered the bidding directory in Hubei Province, widely used in Wuhan, Hubei Province. Because of the antibacterial effect of gatifloxacin, the advantages of good clinical efficacy and safety, coupled with convenient medication, only administered once daily, patient compliance is good, so many manufacturers, fierce competition in the hospital, will now Our hospital gatifloxacin application analysis. 1 data and methods